Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
Streamline your rAAV workflows with simplified lysate purification – enabling faster, more reliable analytics for upstream samples.
news

New acquisition to support global gene therapy manufacturing

1
SHARES

Acquisition of Forge Biologics by Ajinomoto Co., Inc. is set to extend global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc.

New acquisition to support global gene therapy manufacturing

Credit: IgorGolovniov / Shutterstock.com

Ajinomoto Co., Inc. is set to acquire Forge Biologics, a viral vector and plasmid contract development and manufacturing organisation (CDMO) and clinical-stage therapeutics company. According to Forge Biologics, the acquisition is an all-cash deal for $620 million, which is Forge’s enterprise value on a cash-free and debt-free basis.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The equity value attributable to unitholders of Forge Biologics is approximately $554 million. This is anticipated to be the amount adjusted when the acquisition deal is executed.

Ajinomoto’s acquisition of Forge Biologics extends global capabilities in adeno-associated viruses (AAV) and plasmid gene therapy manufacturing. It will help to diversify and strengthen the company’s current contract development and manufacturing services.

All development and manufacturing of these products is done at Forge’s 200,000ft2 current good manufacturing practice (cGMP) facility in Columbus, Ohio in the US.

Impact of the acquisition agreement

Timothy Miller, PhD, CEO, President, and Co-founder of Forge Biologics stated that the CDMO is “excited” to join Ajinomoto Co. to continue expanding its business of “helping innovators manufacture much needed genetic medicines”. Miller added that the acquisition will help to advance its mission into the next global stage of development to expand its capabilities.

Yasuyuki Otake, Corporate Executive, General Manager of Bio-Pharma Services Department of Ajinomoto Co stated that the company is looking forward to working with Forge and its specialised manufacturing facility because “Forge brings to Ajinomoto an entirely new capability that will vitally enhance our Bio-Pharma Services business and help create new value through innovative solutions for communities and society,” commented Otake.

The new acquisition deal is expected to be completed by the end of the fourth quarter of 2023, subject to customary closing conditions, including regulatory approvals.

In addition to cGMP viral vector and plasmid DNA manufacturing, Forge Biologics also provides other services, including end-to-end process and analytical development, final fill, as well as regulatory consulting support.

Share via
Share via